Andros Pharmaceuticals Co.,Ltd (6917.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan · ISIN TW0006917008

Price
32.10 TWD
Market cap
1.77 bn TWD
P/E (2025)
–
P/S (2025)
319.80
Dividend yield
0.00 %
Net margin
-969.29 %
Return on equity (ROE)
-10.43 %
Return on assets (ROA)
-9.62 %

Andros Pharmaceuticals Co.,Ltd financials

Fiscal year20242025
Revenue203,000.00 TWD5.55 m TWD
Gross profit10,000.00 TWD1.80 m TWD
Operating income-89.61 m TWD-75.64 m TWD
EBIT-77.76 m TWD-53.25 m TWD
Net income-78.28 m TWD-53.78 m TWD
Diluted EPS – continuing operations-1.70 TWD-0.97 TWD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Andros Pharmaceuticals Co.,Ltd

Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain. The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.